Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
In this study, the investigators aimed at evaluating the role of bitter taste receptors in the gastrointestinal tract (GIT). Intragastric or intraduodenal administration of denatonium benzoate (DB) or quinine hydrochloride were compared with placebo administration for their effects on lingual sensitivity, gastrointestinal motility (both in the fasted and fed state), gut hormone release (motilin, ghrelin, glucagon-like peptide-1 (GLP-1) and cholecystokinin (CCK)) and food intake. Differences between lean and obese subjects will be evaluated.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Denatonium benzoate intragastric | Active Comparator | 1 µmol/kg bodyweight (10mM) was administered as a bolus into the stomach through a nasogastric feeding tube. |
|
| Quinine hydrochloride intragastric | Active Comparator | 10 µmol/kg bodyweight (100mM) was administered as a bolus into the stomach through a nasogastric feeding tube. |
|
| Tap water intragastric | Placebo Comparator | An equal amount of tap water was administered as a bolus into the stomach through a nasogastric feeding tube. |
|
| Denatonium benzoate intraduodenal | Active Comparator | 1 µmol/kg bodyweight (10mM) was administered as a bolus into the proximal part of the duodenum through a nasogastric feeding tube. |
|
| Quinine hydrochloride intraduodenal | Active Comparator | 10 µmol/kg bodyweight (100mM) was administered as a bolus into the proximal part of the duodenum through a nasogastric feeding tube. |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Denatonium benzoate | Drug |
| ||
| Quinine hydrochloride |
| Measure | Description | Time Frame |
|---|---|---|
| Change in gastrointestinal motility measured by antroduodenal high-resolution manometry | 2 hours after administration, continuous measurement with high resolution manometry |
| Measure | Description | Time Frame |
|---|---|---|
| Change in gut hormone release measured by specific radioactive immunoassays | 2 hours after administration, blood sample every 10 min | |
| Change in food intake measured by the caloric content of the meal | ad libitum food intake for 1 hour, 40 min after administration |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Jan Tack, Prof | Universitaire Ziekenhuizen KU Leuven | Principal Investigator |
Not provided
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 28148502 | Derived | Deloose E, Janssen P, Corsetti M, Biesiekierski J, Masuy I, Rotondo A, Van Oudenhove L, Depoortere I, Tack J. Intragastric infusion of denatonium benzoate attenuates interdigestive gastric motility and hunger scores in healthy female volunteers. Am J Clin Nutr. 2017 Mar;105(3):580-588. doi: 10.3945/ajcn.116.138297. Epub 2017 Feb 1. |
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D009765 | Obesity |
| ID | Term |
|---|---|
| D050177 | Overweight |
| D044343 | Overnutrition |
| D009748 | Nutrition Disorders |
| D009750 | Nutritional and Metabolic Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| C043414 | denatonium |
| D011803 | Quinine |
| ID | Term |
|---|---|
| D002930 | Cinchona Alkaloids |
| D000470 | Alkaloids |
| D006571 | Heterocyclic Compounds |
| D011812 | Quinuclidines |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Tap water intraduodenal | Placebo Comparator | An equal amount of tap water was administered as a bolus into the proximal part of the duodenum through a nasogastric feeding tube. |
|
| Drug |
|
| Tap water | Drug |
|
| Change in subjective hunger and satiety scores measured by visual analogue scales of 100 mm | 2 hours after administration, assessment every 5 min |
| D001835 |
| Body Weight |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D006572 |
| Heterocyclic Compounds, Bridged-Ring |
| D011804 | Quinolines |
| D006574 | Heterocyclic Compounds, 2-Ring |
| D000072471 | Heterocyclic Compounds, Fused-Ring |